|
The Department of Pharmaceuticals (DoP), along with the Federation of Indian Chambers of Commerce & Industry (FICCI) and Indian Pharmaceutical Alliance (IP Alliance), will be organising the 9th edition of India Pharma 2026, a flagship initiative aimed at promoting India’s pharmaceutical sector, on April 13th and 14th, 2026, at Federation House, New Delhi.
This time, the theme of the event is "Discover in India: Leapfrogging life-sciences innovation," aligned with India’s vision of becoming a global innovation hub. The theme emphasizes transformative advancements in life sciences that can enhance healthcare access, drive economic growth, and strengthen global health security, said FICCI announcing the event details.
"As the 'Pharmacy of the World', India has consistently proven its mettle in providing affordable, high-quality medicines to the world. The 2026 edition of India Pharma serves as a strategic catalyst to transition the Indian pharmaceutical sector from a 'volume-driven' model to a 'value-and-innovation-driven' global powerhouse," said the Federation.
The initiative is designed to highlight India’s manufacturing excellence and its burgeoning R&D ecosystem. By bringing together global leaders, policymakers, and researchers, the event aims to foster an environment conducive to drug discovery, complex generics, and biosimilars.
The key highlights of the 9th Edition of India Pharma 2026 include CEO’s roundtable with representation from the ministry of chemicals and fertilisers, Policy thrust for catalysing innovation, Unleashing India’s CRDMO potential, Enabling regulatory ecosystem to foster innovation, Developing a vibrant pharma financing ecosystem, and Harnessing AI and other technologies for disruptive innovation.
The event will benefit the policy makers, regulators and public health officials, innovator and pharmaceutical manufacturers, stakeholders from the academia, research institutions and scientists, policy think tanks, and investors, among others.
India is 3rd largest global player in drugs and pharmaceuticals by volume estimated, and exports account for 50 per cent of this. It is anticipated to reach a size of more than double to $130 billion by 2030, says FICCI.
India's pharmaceutical exports reached $27.85 billion in FY24, growing 9.66 per cent. Pharmaceuticals account for 9.67% of India's merchandise exports; drug formulations and biologicals are the second largest export. Ten of the top 25 global generic drug companies are from India. Market size of India pharmaceuticals industry is expected to reach $65 billion by 2024, and $130 billion by 2030.
The sector offers lower cost without compromising on quality as is reflected by the fact India has the highest number of United States Food and Drug Administration (FDA) approved pharmaceutical plants outside the US and also a significant number of World Health Organization (WHO) Good Manufacturing Practices (GMP)- compliant plants as well as plants approved by regulatory authority of other countries, it added.
India accounts for 60 per cent of global vaccine production, contributing 40 to 70 per cent of the WHO demand for diphtheria, tetanus and pertussis (DPT) and Bacillus Calmette-Guérin (BCG) vaccines, and 90 per cent of the WHO demand for the measles vaccine. There are 500 API manufacturers contributing about 8% in the global API Industry. India is the largest supplier of generic medicines and manufactures about 60,000 different generic brands across 60 therapeutic categories and accounts for 20% of the global supply of generics, said the Federation.
India's 500 API manufacturers contribute 8% to the global API industry. Within the immense potential for growth, pharmaceuticals sector is set to attain new heights in a post-pandemic world and elevate its position on the value chain by delivering affordable and quality- assured medicines and addressing the unmet needs of patients across the globe.
|